NewsRoom Articles - Page 135 of 202

MondayAug 09, 2021 1:12 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise

InMed announced a non-binding letter of intent to acquire BayMedica Inc. The move is designed to grow InMed’s market presence and strengthen its operations The two companies have had a reciprocal research collaboration that dates back to November 2020 InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028 InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company committed to developing cannabinoid-based pharmaceutical drug candidates. It also manufactures technologies for pharmaceutical-grade rare cannabinoids. It is known for creating a pipeline of cannabinoid-based pharmaceutical drug candidates to treat various…

MondayAug 09, 2021 12:10 pm

Brain Scientific Inc. (BRSF) Positioned to Disrupt EEG Market with Cost-Effective Brain Imaging Devices

Brain Scientific poised to disrupt neurology market with two new FDA-cleared patented products that provide cost-effective brain imaging in any setting Current global market for EEG devices estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026 With a focus on developing innovative and proprietary medical devices and software, Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with two new FDA-cleared products that provide next-generation solutions to the neurology market. Already patented in the United States, China and…

FridayAug 06, 2021 1:35 pm

New Model Could Result in More Customized Bladder Cancer Treatments

Researchers from the Uppsala University have developed a new mouse model that can be used to study the factors that contribute to the progression of immune-system activation and bladder cancer in humans as the tumor grows. Through this model, the researchers have learned how proteins change prior to, during and after tumor development in the bladder wall. Their findings were published in the “PLOS ONE” journal. The study’s principal investigator Sara Mangsbo stated that the model was designed to demonstrate the harmful mutations observed in bladder cancer patients and to contain mutations that drive tumor growth, known as specific oncogenes.…

FridayAug 06, 2021 9:00 am

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021

Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1 The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings The global cancer diagnostics market size is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening, detection, and cancer treatment, announced that it experienced strong growth in test volume in the…

FridayAug 06, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine Cannabis in sports medicine took center stage at the Tokyo Olympics American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group's dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps…

ThursdayAug 05, 2021 3:01 pm

Neuron Activation Timing Could Change Treatment for Brain Conditions

Research recently published in the “Cell” journal shows the existence of a neural code known as phase precession in the human brain. Phase precession refers to a neurophysiological process in which neurons signal information by changing the timing in which they activate. This timing code has been observed in rodents navigating through spaces, with researchers theorizing that it may form the basis for how the brain represents sequences. This is the first time phase precession has been observed in humans. The study was conducted by Dr. Itzhak Fried, a neurosurgery professor at the UCLA David Geffen School of Medicine, in…

ThursdayAug 05, 2021 1:23 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters…

ThursdayAug 05, 2021 12:14 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Marks Milestone Moment as First Psychedelic Biotech to Trade on NYSE American Exchange

Company announces official approval for its common shares to be listed, traded on NYSE American Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader Companies that list on NYSE American can leverage a wide range of advantages In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading…

ThursdayAug 05, 2021 12:05 pm

Brain Scientific Inc.’s (BRSF) Rapid Response EEG Devices Provide Cost-Effective Solution for Neurology Market

Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026 Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market. Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive…

WednesdayAug 04, 2021 2:15 pm

AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening

Summary After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. According to US marketing research firm Frost-Sullivan, AnPac Bio ranked top three globally in terms of clinical and commercial test sample numbers in the space of new cancer detection technologies in 2019. In the next five years, AnPac Bio strives to become a global leader…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise

Brain Scientific Inc. (BRSF) Positioned to Disrupt EEG Market with Cost-Effective Brain Imaging Devices

New Model Could Result in More Customized Bladder Cancer Treatments

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021

RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

Neuron Activation Timing Could Change Treatment for Brain Conditions

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Marks Milestone Moment as First Psychedelic Biotech to Trade on NYSE American Exchange

Brain Scientific Inc.’s (BRSF) Rapid Response EEG Devices Provide Cost-Effective Solution for Neurology Market

AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search